- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07792317
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation (NEWHOPE)
A Single-center, Non-randomized, Uncontrolled Pilot Study on Hypothermic Machine Perfusion With Omnisol Preservation Solution of Deceased Donor Kidneys Prior to Transplantation
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function.
Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Omnisol organ preservation solution was developed to improve kidney transplant outcomes. It is an extracellular-type solution containing the synthetic colloid polyethylene glycol (PEG) and several impermeants for optimal osmotic pressure. It further contains multiple buffering agents for the prevention of intracellular acidosis, antioxidants for the minimization of ROS-induced injury and amino acids and other substrates for supporting the cell metabolism during hypothermic machine perfusion (HMP) as well as the provision of substrates for regeneration of high-energy phosphate compounds during graft reperfusion.
Continuous HMP using the XVIVO Kidney Assist Transport is routinely used for deceased donor kidney preservation in the Netherlands.
This is a single-center, non-randomized, uncontrolled, open-label first-in-human clinical investigation evaluating Omnisol as an organ preservation solution for continuous HMP of deceased donor kidneys before transplantation.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Benedict Doorschodt, MD
- Numéro de téléphone: +31 6 54658420
- E-mail: bd@vivalyx.com
Lieux d'étude
-
-
-
Rotterdam, Pays-Bas, 3015
- Recrutement
- Erasmus Medical Center
-
Contact:
- Robert Minnee, MD PhD
- Numéro de téléphone: +31-10-70 31149
- E-mail: r.minnee@erasmusmc.nl
-
Chercheur principal:
- Robert Minee
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion for donor:
- Donor age > 18 years
- Brain Death (DBD) or Circulatory Death < 50 years (DCD<50)
- Accepted for transplantation according to local criteria
Inclusion for recipient:
- Male or female, age > 18 years
- Able and willing to comply with all study requirements (in opinion of investigator or deputy)
General inclusion criteria applicable to kidney transplantation:
- Listed for renal transplantation due to end stage renal disease on the Eurotransplant (ET) list
- Fit to proceed with kidney transplantation (in opinion of investigator or deputy)
Exclusion for donor:
- Donor kidneys accepted as a pair for dual transplant
- Circulatory Death ≥ 50 years (DCD 50+)
- Participation in an investigational study likely to affect interpretation of the trial data
Exclusion for recipient:
- General exclusion criteria applicable to kidney transplantation
- Breast-feeding or pregnant, as confirmed by pregnancy test or blood test, or plans to become pregnant over the study period
- Participation in an investigational study likely to affect interpretation of the trial data
- Mental disabilities that may affect the understanding of the study requirements including the ability to adhere to medication regime (in opinion of investigator or deputy)
- Undergoing living donor kidney transplantation
- Undergoing dual kidney transplantation
- Undergoing transplantation of other organ(s) in addition to the kidney
- Highly immunized patients with vPRA > 85% (as confirmed by routine cross-matching test)
- Other substantial risk of transplant not proceeding (in opinion of investigator or deputy)
- Other significant disease or disorder which, in the opinion of the Investigator, may: (i) put the participant at risk by participating in the study; (ii) influence the result of the study; (iii) affect the participant's ability to participate in the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Hypothermic machine perfusion with Omnisol
Prior to transplantation, kidneys from deceased donors will undergo continuous nonoxygenated HMP with Omnisol using the XVIVO Kidney Assist Transport.
|
Omnisol for HMP of deceased donor kidneys
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Delayed Graft Function
Délai: Within 7 days post-transplantation.
|
Incidence of delayed graft function, defined as the need for dialysis within the first week after transplantation, excluding one-time dialysis for hyperkalemia or volume overload.
|
Within 7 days post-transplantation.
|
|
Graft Survival
Délai: 30 days post-transplantation.
|
30-day graft survival (censored and uncensored for recipient death).
|
30 days post-transplantation.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Graft Survival
Délai: 3, 6 and 12 months post-transplantation.
|
Graft survival (censored and uncensored for recipient death).
|
3, 6 and 12 months post-transplantation.
|
|
Recipient survival
Délai: 30 days, 3, 6 and 12 months post-transplantation.
|
Rate of recipient survival.
|
30 days, 3, 6 and 12 months post-transplantation.
|
|
Kidney Graft Function Assessed by eGFR
Délai: 30 days, 3, 6 and 12 months post-transplantation.
|
Estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI formula.
|
30 days, 3, 6 and 12 months post-transplantation.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Insuffisance rénale chronique
- Conditions pathologiques, signes et symptômes
- Insuffisance rénale
- Insuffisance rénale chronique
Autres numéros d'identification d'étude
- OMNISOL_HMP_NL
- NL-OMON57467 (Autre identifiant: Overview of Medical Research in the Netherlands (OMON))
- NL87460.000.24 (Autre identifiant: The Central Committee on Research Involving Human Subjects (CCMO))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .